The 6th edition of the World Health Organization Classification of Soft Tissue and Bone Tumors (STB6) integrates the latest scientific and molecular discoveries with decades of pathological expertise to establish a globally accepted common language for diagnosis and clinical behavior. In this volume, the “essential” an...
J. Hornick, J. Bovée, C. Antonescu et al.· American Journal of Surgical...· 0 citations
The key role of fusion genes in driving both tumourigenesis and morphological subtypes of HACa and HA are demonstrated, and additional molecular drivers of de novo HACa are identified.
I. Ferreira, J. Billington, M. del Castillo Velasco-Herrera et al.· British Journal of Dermatolo...· 0 citations
BACKGROUND
Primary breast angiosarcoma (PBA) is rare, and limited data exist because studies often combine primary and secondary angiosarcoma patients.
METHODS
For patients with PBA who received care at a comprehensive cancer center from 1991 to 2025 and underwent surgical resection, this retrospective study collecte...
Rick D. Vavolizza, A. Subramaniam, Min Yi et al.· Annals of Surgical Oncology· 0 citations
Importance
Leiomyosarcoma is a rare and heterogeneous malignant mesenchymal neoplasm associated with substantial morbidity and mortality. Given recent advances in biologic understanding and the complexity of leiomyosarcoma, a consensus-driven approach is needed to harmonize management and address remaining clinical and...
F. Campos, R. Gladdy, Annie Achee et al.· JAMA Oncology· 0 citations
Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an ultra-rare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasible. We investigated whether wild-type epidermal growth factor receptor (EGFR) is a therapeutically...
N. Zacharias, Eric S Rupe, Xinyue Chen et al.· Clinical Cancer Research· 0 citations
It is demonstrated that uveal melanoma progression reflects an integrated CN-transcriptional ecosystem extending beyond chromosome 3 loss, with cytoband-level genomic evolution shaping malignant fitness and therapeutic response.
Johnathon L. Rose, Sanjana Srinivasan, A. Cooper et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.